These combination treatment strategies can improve clinical outcomes in HR+/HER2+ or ERBB2-mutant breast cancer, potentially overcoming resistance to ET arising from crosstalk between the ER and HER2 signaling pathways. Here, ERBB2 is linked to breast cancer.